Literature DB >> 15230693

Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine.

Antonio Pisani1, Paola Bonsi, Giuseppina Martella, Cristiano De Persis, Cinzia Costa, Francesco Pisani, Giorgio Bernardi, Paolo Calabresi.   

Abstract

PURPOSE: Alterations in neuronal calcium (Ca2+) homeostasis are believed to play an essential role in the generation and propagation of epileptiform events. Levetiracetam (LEV) and lamotrigine (LTG), novel antiepileptic drugs (AEDs), were tested on epileptiform events and the corresponding elevations in intracellular Ca2+ concentration ([Ca2+]i) recorded from rat neocortical slices.
METHODS: Electrophysiological recordings were performed from single pyramidal neurons from a slice preparation. Spontaneous epileptiform events consisting of long-lasting, repetitive paroxysmal depolarization shifts (PDSs) and interictal spike activity were induced by reducing the magnesium concentration from the solution and by adding bicuculline and 4-aminopyridine. Simultaneously, microfluorimetric measurements of [Ca2+]i were performed. Optical imaging with Ca2+ indicators revealed a close correlation between Ca2+ transients and epileptiform events.
RESULTS: Both LEV and LTG were able to reduce both amplitude and duration of PDSs, as well as the concomitant elevation in [Ca2+]i, in a dose-dependent fashion. Whole-cell patch-clamp recordings from isolated neocortical neurons revealed that LEV significantly reduced N-, and partially P/Q-type high-voltage-activated (HVA) Ca2+ currents, whereas sodium currents were unaffected. Interestingly, the inhibitory effects of LEV were mimicked and occluded by LTG or by a combination of omega-conotoxin GVIA and omega-agatoxin IVA, selective blockers of N- and P/Q-type HVA channels, respectively, suggesting a common site of action for these AEDs.
CONCLUSIONS: These results demonstrate that large, transient elevations in neuronal [Ca2+]i correlate to epileptiform discharges. The antagonistic effects of LEV and LTG on [Ca2+]i overload might represent the basis for their anticonvulsant efficacy and could preserve neuronal viability. Copyright 2004 International League Against Epilepsy

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15230693     DOI: 10.1111/j.0013-9580.2004.02204.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  31 in total

1.  A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence.

Authors:  E Sherwood Brown; Prabha Sunderajan; Lisa T Hu; Sharon M Sowell; Thomas J Carmody
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

Review 2.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 3.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

4.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

Review 5.  Development of the calcium plateau following status epilepticus: role of calcium in epileptogenesis.

Authors:  Nisha Nagarkatti; Laxmikant S Deshpande; Robert J DeLorenzo
Journal:  Expert Rev Neurother       Date:  2009-06       Impact factor: 4.618

6.  Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus.

Authors:  Chun-Yao Lee; Chih-Chuan Chen; Horng-Huei Liou
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 7.  Seletracetam (UCB 44212).

Authors:  Barbara Bennett; Alain Matagne; Philippe Michel; Michèle Leonard; Miranda Cornet; Marie-Anne Meeus; Nathalie Toublanc
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 8.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

9.  Down-regulation of BK channel expression in the pilocarpine model of temporal lobe epilepsy.

Authors:  Luis F Pacheco Otalora; Eder F Hernandez; Massoud F Arshadmansab; Sebastian Francisco; Michael Willis; Boris Ermolinsky; Masoud Zarei; Hans-Guenther Knaus; Emilio R Garrido-Sanabria
Journal:  Brain Res       Date:  2008-01-18       Impact factor: 3.252

10.  Levetiracetam in stiff-person syndrome.

Authors:  Gianpietro Sechi; Marianna Barrocu; Maria G Piluzza; Giovanni A Cocco; Giovanni A Deiana; Gian Franco Sau
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.